A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various serious medical conditions.

Regeneron’s move into the corporate VC area comes as it is still reaping the benefits of impressive sales growth from drugs like immunology therapy Dupixent (dupilumab) and cancer therapy ...

CNBC Select will update as changes are made public. With a high-yield savings account, you can get a solid interest rate and your money grows even faster thanks to compound interest — which lets ...

Olympic gold medalist Tara Davis-Woodhall hosts a high school track meet at her alma mater in which more than 30 schools are expected to participate. CIF Southern Section boys’ and girls’ high ...

Sanofi and Regeneron have been collaborating since 2003, with the partnership generating some of Sanofi’s most prominent drugs including top-selling Dupixent (dupilumab) for eczema and asthma ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Commissions do not affect our editors' opinions or evaluations. The best high-yield savings account is Capital One 360 Performance Savings Account™, earning the top rating of 5.0 stars in our study.

FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S ...